PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers

An Open-label, Crossover, Phase 1 Clinical Trial to Evaluate the Pharmacokinetic/Pharmacodynamic Drug-drug Interactions and Safety/Tolerability of Epaminurad and C2406 When Co-administered in Healthy Adults

A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and C2406 in Healthy Volunteers

Inclusion Criteria:

1. Age: 19~50
2. Weight: between 50.0 kg~90.0 kg, Body Mass Index(BMI): 18.0 kg/m^2 or heavier and below 30.0 kg/m^2

Exclusion Criteria:

1. Medical history- chronic liver disease, acute gout attack, uric acid stone, diabetes, hypertension, hyperlipidemia or lipid abnormality

2. Clinical examination

   • eGFR (CKD-EPI) < 90mL/min/1.73m^2
   • Serum uric acid < 3 mg/dL or > 7 mg/dL
   • AST (SGOT), ALT (SGPT) > upper limit of normal ranges X 1.5
   • Total bilirubin, γ-GTP > upper limit of normal ranges X 1.5
   • CK > upper limit of normal ranges X 2
   • Positive serologic results